Roth Mkm reaffirmed a “buy” rating and set a $22.00 target price on shares of Orthofix Medical in a report on Wednesday, February 26th. Finally, StockNews.com raised Orthofix Medical from a ...

The Orthofix SpinalStim you’re seeing here was given to me by a friend after their doctor said the therapy could be cut short. This provided a somewhat rare opportunity to observe the device ...

LEWISVILLE, Texas, April 15, 2025--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its first quarter 2025 ...

Orthofix Medical Inc. operates as a medical technology company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments ...

However, management has either reiterated or increased its long-range plan (LRP) targets that were initially set during the third-quarter earnings call of 2024. During the quarter, Orthofix ...

Orthofix has also set ambitious financial targets for 2027, aiming for a 6% to 7% compound annual growth rate (CAGR) in net sales and mid-teens adjusted EBITDA margins. The company has expressed ...

LEWISVILLE, Texas, March 19, 2025--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced it has received U.S. Food and Drug ...

Orthofix Medical (NASDAQ:OFIX) just reported results for the first quarter of 2024. Orthofix Medical reported earnings per share of -33 cents. This met the analyst estimate for EPS of -33 cents.

Looking further ahead, Orthofix has set ambitious targets for 2027. The company aims to achieve mid-teens adjusted EBITDA as a percentage of sales by the full year 2027. Additionally, management ...

Company to Host Conference Call on Tuesday, May 6, 2025 at 8:30 am Eastern Time Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Despite these positive results, Orthofix provided guidance for 2025 that was slightly below analyst expectations. However, management has either reiterated or increased its long-range plan (LRP) ...